Peritoneal surface oncology is a specialised field of cancer treatment focusing on malignancies that spread to the peritoneum, the thin lining of the abdominal cavity. The peritoneum is a delicate yet vital structure, providing a protective covering for abdominal organs and acting as a conduit for fluid exchange. Unfortunately, when cancer cells reach this surface, they behave differently compared to their primary tumor sites. This makes peritoneal cancers complex, aggressive, and historically difficult to treat.

To grasp the concept better, imagine the peritoneum as a clean sheet covering furniture in a room. If dust (cancer cells) settles on the sheet, it spreads widely, covering everything underneath. Similarly, peritoneal malignancies often blanket abdominal organs, making complete eradication a challenge.

The term Peritoneal Surface Malignancy (PSM) encompasses various cancers, including primary tumors like peritoneal mesothelioma and secondary involvement from cancers such as colorectal, ovarian, and gastric malignancies. Unlike metastases to other organs, peritoneal involvement often doesn’t follow the same blood-borne or lymphatic routes but spreads within the abdominal cavity itself.

What makes peritoneal surface oncology unique is the multidisciplinary approach it demands. Traditional oncology once considered peritoneal metastases as a terminal stage with limited options, but advancements like Cytoreductive Surgery (CRS) combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) have shifted the paradigm. Today, patients once deemed “beyond treatment” can achieve long-term survival and improved quality of life.

In the following sections, we’ll dive deeper into how peritoneal cancers develop, who they affect, the diagnostic journey, and the modern therapies reshaping outcomes.

---

Epidemiology and Incidence

Peritoneal surface malignancies may not be as common as lung, breast, or colon cancer, but their impact is disproportionately severe due to late detection and limited awareness. Globally, thousands of new cases are reported annually, with many more likely underdiagnosed because early symptoms mimic benign abdominal conditions.

Colorectal cancer is one of the most frequent sources of peritoneal metastasis. Studies estimate that up to 15% of colorectal cancer patients eventually develop peritoneal spread. Similarly, ovarian cancer has a notorious tendency to seed the peritoneum, with over 70% of advanced-stage cases presenting with peritoneal involvement at diagnosis. Gastric cancers also show high rates of peritoneal dissemination, particularly in Asian populations where gastric cancer incidence is higher.

Regional variations exist. In Western countries, colorectal and ovarian cancers dominate as sources of peritoneal disease, whereas in Asia, gastric cancer leads to higher peritoneal spread cases. Primary peritoneal mesothelioma, although rare, has been linked to asbestos exposure and tends to appear more in men working in industrial settings.

Another important aspect is the rising awareness and better diagnostic tools that have led to increased reporting. What was once dismissed as “carcinomatosis” with little hope is now being actively classified, researched, and treated. The creation of specialized peritoneal oncology centers worldwide has also contributed to better data collection and patient outcomes.

Despite these advances, the overall incidence is still difficult to pin down, largely due to underreporting and misclassification. However, the global oncology community agrees that peritoneal malignancies are a significant health concern, with survival outcomes heavily dependent on timely diagnosis and access to specialized care.

---

Pathophysiology of Peritoneal Malignancy

The spread of cancer to the peritoneal surface doesn’t occur randomly. It follows well-studied biological pathways. Most peritoneal metastases arise when cancer cells from a primary tumor in the gastrointestinal tract or reproductive system detach and shed into the peritoneal cavity. These free-floating cells then implant themselves onto the peritoneal lining.

Think of this like seeds being blown into a garden. If the soil (peritoneum) is fertile, the seeds (cancer cells) take root and grow. The “soil and seed theory” is widely used to explain how peritoneal metastases form. The peritoneal fluid circulation further assists in distributing these cells across the abdominal cavity, making multiple organ surfaces vulnerable.

The tumor microenvironment plays a critical role. Cancer cells don’t act alone; they manipulate immune cells, fibroblasts, and blood vessels within the peritoneum to create a supportive ecosystem. They release growth factors and cytokines that help them stick to surfaces, invade tissues, and resist chemotherapy.

Additionally, peritoneal tumors exhibit unique biological behavior compared to metastases in the liver or lungs. They grow in a sheet-like fashion, coating surfaces rather than forming discrete lumps. This makes surgical removal particularly complex, as surgeons must meticulously strip away tumor deposits from organs without compromising function.

Another concerning aspect is chemotherapy resistance. The peritoneal cavity acts as a sanctuary site where systemic chemotherapy often struggles to penetrate effectively. This resistance has fueled the development of local treatment strategies such as HIPEC and PIPAC, which deliver high concentrations of chemotherapy directly to the site of disease.

Understanding the pathophysiology isn’t just academic—it directly influences treatment design. By targeting the microenvironment, improving drug delivery methods, and refining surgical techniques, oncologists continue to push the boundaries of survival for peritoneal surface malignancies.

---

Clinical Presentation and Diagnosis

Peritoneal surface malignancies are often silent invaders. Symptoms typically appear late, making early detection a major challenge. The initial signs are vague—abdominal bloating, mild discomfort, or changes in bowel habits. Patients often dismiss these as indigestion, irritable bowel syndrome, or normal aging-related changes. By the time more specific symptoms like ascites (fluid buildup in the abdomen), weight loss, or bowel obstruction appear, the disease is usually advanced.

From a clinical perspective, doctors rely on multiple diagnostic tools:

1. Imaging Techniques: CT scans remain the standard imaging tool, though MRI and PET scans provide additional details. Unfortunately, small peritoneal nodules often escape detection, meaning imaging may underestimate disease extent.

2. Biomarkers: Blood tests for tumor markers like CEA, CA-125, or CA 19-9 are supportive but not definitive. They help monitor disease progression but rarely confirm diagnosis alone.

3. Laparoscopy: This minimally invasive surgical technique allows direct visualization and biopsy of peritoneal lesions. It’s often considered the gold standard for diagnosis because it gives real-time insights into disease spread.

4. Cytology: Analysis of ascitic fluid can sometimes reveal malignant cells, though negative results don’t rule out disease.

One useful tool is the Peritoneal Cancer Index (PCI), which measures tumor distribution and volume across 13 abdominal regions. This scoring system guides treatment decisions, particularly regarding eligibility for cytoreductive surgery and HIPEC.

Early detection remains a significant hurdle. Because symptoms are non-specific, many patients are diagnosed incidentally during surgery for another condition or when complications force urgent medical attention. This delay often reduces treatment options and impacts survival.

Public awareness and better screening strategies for high-risk patients could improve outcomes in the future. Until then, the diagnostic challenge remains one of the greatest obstacles in peritoneal surface oncology.